Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Norway / NCT00119912
Active, not recruiting Not applicable

NORCCAP: Norwegian Colorectal Cancer Prevention Trial

NCT00119912 · tracked via the Priya Life Science Norway tracker
Sponsor
Norwegian Institute of Public Health
Phase
Not applicable
Started
1999-01-01
Last updated
2026-04-14

Condition(s) studied

Colorectal CancerAdenoma

Investigational drug(s) / intervention(s)

A 1 Intervention arm Flex SigA 2 Intervention arm Flex Sig + iFOBT

A 1 Intervention arm Flex Sig: Screening by flexible sigmoidoscopy

A 2 Intervention arm Flex Sig + iFOBT: In addition to Flexible Sigmoidoscopy, half of arm A (randomised 1:1) is invited to provide stool samples for FOBT

Study summary

The purpose of this study is to see if screening with flexible sigmoidoscopy (a flexible viewing tube) may reduce large bowel cancer and cancer deaths. The researchers also want to see if the addition of screening for occult blood in stools may contribute further to this aim. Additionally, the researchers also want to see to which extent (and in which direction) the study may influence overall endoscopic activity in the general population in the screening area and in areas where controlled screening is not established.

Eligibility

Sex
ALL
Min age
50 Years
Max age
64 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Men and women * Living in Oslo or Telemark * Age 50-64 years Exclusion Criteria: * Patients with previous open colorectal surgery (resections, enterostomies) * Individuals in need of long lasting attention and nursing services (somatic or psychosocial reasons, mental retardation) * On-going cytotoxic treatment or radiotherapy for malignant disease * Severe chronic cardiac or lung disease (NYHA III-IV) * Patients with heart valve replacement on life long anticoagulant therapy * A coronary event during the last 3 months if having lead to hospitalisation * Cerebrovascular accident during the last 3 months * Resident abroad

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Institute of Population-based Cancer Research Oslo Norway

More Norwegian Institute of Public Health trials in Norway

MEST : A School- Based Health Literacy Intervention Trial Starting soon
Targeting Lifestyle to Improve Colorectal Cancer Screening Starting soon
Guided Internet-based Interventions in Primary Care Effectiveness-implementation Randomized Controlled Trial Active, not recruiting
Coping After Breast Cancer - a Randomized Clinical Trial With Two Digital Interventions Recruiting
Pilot Study of a National Screening Programme for Bowel Cancer in Norway Active, not recruiting

Other trials for the same condition

Partial Liver Segment 2/3 Transplantation Study Recruiting
Assessment of Clinically Related Outcomes and Biomarker Analysis for Translational Integration in Colorectal Cancer Recruiting
Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer Recruiting
HAI-Floxuridine, or Liver-Tx, Combined With 2nd Line Chemotherapy Versus 2nd Line Chemotherapy Alone for Patients With Colorectal Liver Metastases and Heavy Tumour Burden. Active, not recruiting
Circulating Tumour DNA (ctDNA) as a Prognostic and Predictive Marker in Colorectal Cancer - a Pilot Study Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT00119912 on ClinicalTrials.gov ↗ ← All trials in Norway